Volume : 13, Issue : 01, January – 2026

Title:

A COMPREHENSIVE REVIEW OF REPORTED ADR PATTERN AND GLOBAL SAFETY OF ANTIHYPERTENSIVE DRUGS

Authors :

Vaishnavi R, Bharath Krishna K, Thejas H, Ayisha Nidha T M, Surya Lakshmi R, Dr. Sini T Inasu, Anupa M Chandran

Abstract :

Adverse drug reactions (ADRs) represent a critical public health burden, with the FDA’s Adverse Event Reporting System documenting nearly 175,000 deaths and over 1.25 million major adverse events in 2022. Pharmacovigilance, the systematic detection, assessment, and prevention of ADRs, has evolved from traditional spontaneous reporting systems to incorporate advanced methodologies including electronic health records, real-world data analytics, and artificial intelligence. This article provides a comprehensive review of current pharmacovigilance practices, data sources, and global monitoring systems, with particular emphasis on adverse drug reaction patterns across antihypertensive drug classes—the most frequently prescribed medications for hypertension management. The safety profiles of ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, beta-blockers, and direct vasodilators are examined in detail, highlighting class-specific adverse effects and clinical implications. Additionally, emerging artificial intelligence technologies and their role in enhancing signal detection and pharmacovigilance efficiency are discussed. Continued investment in pharmacovigilance infrastructure, particularly in resource-limited settings, combined with advancement of AI-driven detection systems, is essential for strengthening global drug safety surveillance and improving patient outcomes.
Keywords: Pharmacovigilance, Adverse drug reactions, Antihypertensive medications, Drug safety, Artificial Intelligence.

Cite This Article:

Please cite this article in press Vaishnavi R et al., A Comprehensive Review Of Reported Adr Pattern And Global Safety Of Antihypertensive Drugs, Indo Am. J. P. Sci, 2026; 13(01).

REFERENCES:

1. 1 Kommu S, Carter C, Whitfield P. Adverse drug reactions. InStatPearls [Internet] 2024 Jan 10. StatPearls Publishing.
2. Tiwary P, Vanshika K, Sahu C, Haseena S. Review of pharmacovigilance. World Journal of Pharmaceutical and Life Sciences. 2022;8(1):40–53.
3. Yadav L, Dutta S, Sharma J, Rai RK, Matreja PS, Pahwa I. A pharmacovigilance study to analyze the adverse drug reactions in patients treated with antihypertensive drug in tertiary care teaching hospitals. J Popul Therapeut Clin Pharmacol. 2024;31(4):1225-33.
4. 4.Agrawal P, Patrick S, Thomas M, Gupta D, Singh Matreja P, Singh P, et al. Pharmacovigilance monitoring and treatment adherence in patients on antihypertensive drugs at a tertiary care centre. Drugs Context. 2024 Oct 21;13:1–10.
5. Hussain A, Aqil M, Alam MS, Khan MR, Kapur P, Pillai KK. A pharmacovigilance study of antihypertensive medicines at a South delhi hospital. Indian journal of pharmaceutical sciences. 2009 May;71(3):338.
6. Jiao XF, Pu L, Lan S, Li H, Zeng L, Wang H, Zhang L. Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review. Pharmacoepidemiology and Drug Safety. 2024 Mar;33(3):e5768.
7. Wasiullah M, Yadav P, Vishwakarma M, Dubey S, Yadav AK. A comprehensive review of pharmacovigilance: present, past, and future perspectives in patient safety. Int J Pharm Res Appl. 2025 Feb;10(2):2520–2528.
8. Zhao Y, Yu Y, Wang H, Li Y, Deng Y, Jiang G, Luo Y. Machine learning in causal inference: application in pharmacovigilance. Drug safety. 2022 May;45(5):459-76.
9. Kumar A, Khan H. Signal detection and their assessment in pharmacovigilance. Open Pharmaceutical Sciences Journal. 2015 Dec 17;2(1).
10. 10 Rani R, Chand S, Singh A, Kumar D, Devi M. A Review on Signal in Pharmacovigilance. Asian Journal of Pharmaceutical research and development. 2019 Dec 15;7(6):80-4.
11. 11 van der Weg W, von Kreijfelt G, Davidson L, Zwaveling J, Visser LE, van Hunsel FP, Kant AC. Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool. Vaccine. 2025 Aug 30;62:127549.
12. Sunanda S, Prasad SD. Medical Abbreviations Used in Clinical Practice: Common Usage and Standardisation. Journal of Medicine and Health Research. 2025 Aug 21;10(2):171-86.
13. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. International Journal of Clinical Pharmacy. 2025 Aug;47(4):932-44.
14. Sarker A, Ginn R, Nikfarjam A, O’Connor K, Smith K, Jayaraman S, Upadhaya T, Gonzalez G. Utilizing social media data for pharmacovigilance: a review. Journal of biomedical informatics. 2015 Apr 1;54:202-12.
15. Sica DA. Calcium channel blocker‐related peripheral edema: can it be resolved?. The Journal of Clinical Hypertension. 2003 Jul;5(4):291-5.
16. Liang L, Kung JY, Mitchelmore B, Cave A, Banh HL. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta‐analysis. The Journal of Clinical Hypertension. 2022 May;24(5):536-54.
17. Handler J. Resistant Hypertension Responding to Change From Furosemide to Thiazide: Understanding Calcium Channel Blocker–Related Edema. The Journal of Clinical Hypertension. 2010 Sep 7;12(12):949.
18. Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N. ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart Journal. 2020 Sep 1;72(5):345-50.
19. Yilmaz I. Department of Chest Diseases, Division of Immunology and Allergy, Erciyes University School of Medicine, Kayseri, Turkey. Angiotensin-converting enzyme inhibitors induce Cough. Turk. Thorac. J.. 2019;20:36-42.
20. Brown T, Gonzalez J, Monteleone C. Angiotensin‐converting enzyme inhibitor–induced angioedema: a review of the literature. The Journal of Clinical Hypertension. 2017 Dec;19(12):1377-82.
21. 21 Jayasinghe M, Caldera D, Prathiraja O, Jena R, Coffie-Pierre JA, Agyei J, Silva MS, Kayani AM, Siddiqui OS, Coffie-Pierre Jr JA, Agyei Sr J. A comprehensive review of bradykinin-induced angioedema versus histamine-induced angioedema in the emergency department. Cureus. 2022 Nov 30;14(11).
22. Yogesh M, Karangia M, Nagda J, Kankhara F, Parmar PA, Shah N. Thiazide diuretics use & risk of falls & syncope among hypertensives: A retrospective cohort study. The Indian Journal of Medical Research. 2025 Feb 14;161(1):99.
23. Jiao XF, Song K, Jiao X, Li H, Zeng L, Zou K, Zhang W, Wang H, Zhang L. Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system. Frontiers in pharmacology. 2023 Jan 9;13:1045561.
24. Di Fulvio M, Rathod YD, Khader S. Diuretics: a review of the pharmacology and effects on glucose homeostasis. Frontiers in Pharmacology. 2025 Mar 28;16:1513125.
25. Lal M, Sahoo PK, Tiwaskar M, Nisty N, Golwala S, Banerjee S, Krishna R, Mehta A, Kumar A, Garg10 N, Arumugam11 G. Unique Pharmacological Properties and Safety Profiles of Loop Diuretics. The Journal of the Association of Physicians of India. 2024 Sep;72(9S):16-8.
26. Xue Z, Liu X, Liu Q, Yang X, Yu L. A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS). BMC Pharmacology and Toxicology. 2025 Mar 17;26(1):63.
27. Utuama O, Fasuyi O, Strayhorn G, Booker KL. Methyldopa hepatotoxicity: a paradoxical high-risk pregnancy. Journal of Clinical Gynecology and Obstetrics. 2015 Sep 3;4(3):271-4.
28. Chajai I, El Hernoussi Z, Bentalha A, Kettani S. Rebound hypertension after clonidine withdrawal in a pediatric intensive care unit: a case report. Int J Adv Res [Internet]. 2025 May 31 [cited 2026 Jan 4];13(5):860–863.
29. Nachawati D, Leslie SW, Patel JB. Alpha-Blockers. InStatPearls [Internet] 2025 Feb 6. StatPearls Publishing.
30. Zekraoui O, Bhojani N, Zorn KC, Elterman D, Chughtai B. Management and treatment of benign prostatic hyperplasia symptoms: current insights. Research and Reports in Urology. 2025 Dec 31:401-20.
31. Welsh TJ, Mitchell A. Centrally acting antihypertensives and alpha-blockers in people at risk of falls: therapeutic dilemmas—a clinical review. European geriatric medicine. 2023 Aug;14(4):675-82.
32. Nakarmi P, Hermiz J, Vempati R, Chandna S, Bhagat U, Loree S, Gahona CT. Cardiac tamponade due to minoxidil use: a case report and review of the literature. European Journal of Case Reports in Internal Medicine. 2025 May 6;12(6):005379.
33. Solhjoo M, Goyal A, Saliba F, Chauhan K. Drug-Induced Lupus Erythematosus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Updated 2023 Apr 3; cited 2026 Jan 29]..
34. Hariri L, Patel JB. Vasodilators. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Updated 2023 Aug 14; cited 2026 Jan 29].
35. Farzam K, Jan A. Beta Blockers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. [Updated 2023 Aug 22; cited 2026 Jan 29]..
36. Eddin LE, Preyra R, Ahmadi F, Jafari A, Omrani MA, Muanda FT. β‐Blockers and risk of neuropsychiatric disorders: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 2025 Feb;91(2):325-37.
37. Arumugham VB, Shahin MH. Therapeutic Uses of Diuretic Agents. StatPearls.
38. Sun Q, Sever P. Amiloride: A review. Journal of the Renin-Angiotensin-Aldosterone System. 2020 Nov;21(4):1470320320975893.
39. Khurshid F, Aqil M, Alam MS, Kapur P, Pillai KK. Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teaching hospital in New Delhi. DARU J Pharm Sci. 2012 Dec;20(1):34.
40. Menang O, Kuemmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ open. 2023 Sep 1;13(9):e071079.
41. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. International Journal of Clinical Pharmacy. 2025 Aug;47(4):932-44.
42. Alhawassi TM, Krass I, Pont LG. Antihypertensive-related adverse drug reactions among older hospitalized adults. International Journal of Clinical Pharmacy. 2018 Apr;40(2):428-35.